Research programme: stem cell therapy - Kangstem Biotech

Alternative Names: Induced Neural Stem Cells - Kangstem Biotech; iNSC; Second generation Furestem^®- Kangstem Biotech

Latest Information Update: 08 Nov 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Kangstem Biotech
Class Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Atherosclerosis; Osteoarthritis
Research Neurological disorders

Most Recent Events

26 Oct 2016 Early research in Neurological disorders in South Korea (Parenteral) before October 2016 (Kangstem Biotech pipeline, October 2016)
26 Oct 2016 Preclinical trials in Atherosclerosis in South Korea (Parenteral) before October 2016 (Kangstem Biotech pipeline, October 2016)
26 Oct 2016 Preclinical trials in Osteoarthritis in South Korea (Parenteral) before October 2016 (Kangstem Biotech pipeline, October 2016)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.